A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Public ClinicalTrials.gov record NCT03628924. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (HS).
Study identification
- NCT ID
- NCT03628924
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 184 participants
Conditions and interventions
Conditions
Interventions
- Guselkumab dose 1 Drug
- Guselkumab dose 2 Drug
- Guselkumab dose 3 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 4, 2018 (Actual)
- Primary completion
- May 22, 2020 (Actual)
- Completion
- May 22, 2020 (Actual)
- Last update posted
- Feb 4, 2025
2018 – 2020
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Birmingham | Birmingham | Alabama | 35233 | — |
| Olympian Clinical Research | Largo | Florida | 33770 | — |
| Renstar Medical Research | Ocala | Florida | 34470 | — |
| Park Avenue Dermatology | Orange Park | Florida | 32073 | — |
| Olympian Clinical Research | Tampa | Florida | 33614 | — |
| Forcare Clinical Research Inc | Tampa | Florida | 33624 | — |
| Great Lakes Clinical Trials | Chicago | Illinois | 60640 | — |
| Indiana Clinical Trial Center | Plainfield | Indiana | 46168 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Hamzavi Dermatology | Fort Gratiot | Michigan | 48059 | — |
| Central Dermatology | St Louis | Missouri | 63117 | — |
| Clinical Studies Group | Henderson | Nevada | 89052 | — |
| Ohio State University | Columbus | Ohio | 43215 | — |
| Oregon Medical Research Center | Portland | Oregon | 97223 | — |
| University of Pittsburgh Department of Dermatology | Pittsburgh | Pennsylvania | 15213 | — |
| Clinical Partners, LLC | Johnston | Rhode Island | 02919 | — |
| Progressive Clinical Research | San Antonio | Texas | 78213 | — |
| Dermatology Associates of Seattle | Seattle | Washington | 98101-1498 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03628924, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2025 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03628924 live on ClinicalTrials.gov.